Inhibrx (INBX) Director Douglas Forsyth Buys 2,500 Shares

What Happened
Director Douglas Forsyth acquired 2,500 shares of Inhibrx (INBX) in open-market purchases on 2026-09-08. The filing reports a weighted-average purchase price of $114.65 per share for a total reported value of approximately $286,617. This was a purchase (transaction code P), not a sale.

Key Details

• Transaction date: 2026-09-08 (filed the same day).
• Reported weighted-average price: $114.65; individual trades ranged from $114.36 to $114.689 (see footnote).
• Shares acquired: 2,500 shares; total value reported ≈ $286,617.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes:
  • F1: Multiple purchases at prices between $114.36 and $114.689; weighted-average price reported. Reporting person will provide detailed per-trade info on request.
  • F2: The reporting person is trustee of the Forsyth Family Trust dated July 20, 2001, and may be deemed to indirectly beneficially own securities held by that trust.

Context
This was an open-market purchase (direct acquisition) rather than an option exercise or gift. Purchases by insiders can be interpreted by some investors as a positive signal, but they should be considered alongside the director’s role, trust ownership, total holdings, and company fundamentals. For full details or position sizes, consult the complete Form 4 filing or contact the SEC filings database.